bioRxivNeurosciencePreprint
Generation and characterization of human iPSC-derived NPC1I1061T/I10161T i3Neurons as a model for NPC1 disease
Shikha Salhotra, Niamh X. CawleyiD, Christian White, Insung Kang, Anika Prabhu, Cristin D. DavidsoniD, Christopher A. WassifiD, Forbes D. PorteriD
Abstract
Niemann-Pick disease, type C is an autosomal recessive, fatal, neurodegenerative disorder caused by pathological variants in NPC1 or NPC2. Dysfunction of either NPC1 or NPC2 results in impaired intracellular cholesterol transport and subsequent storage of unesterified cholesterol in endolysosomal compartments. Earlier cell-based studies utilized patient fibroblasts to study this disease; however, neuronal cells allow for investigation of the neurodegenerative aspect of NPC1. Expression of neurogenin in induced pluripotent stem cells leads to the generation of i3Neurons (integrated, isogenic, and inducible), allowing for rapid, synchronized growth of homogenous neurons. In this study, we report the development and characterization of a human iPSC-derived NPC1I1061T/I1061Ti3Neuronal model system. NPC1I1061Tis a missense variant resulting in a misfolded protein targeted for proteasomal degradation in the ER. NPC1I1061T/I1061T i3Neurons phenocopied the cellular pathological features of NPC1 disease including endolysosomal cholesterol accumulation, lysosomal morphological changes, and response to the proteostasis modulator, mo56HC. The NPC1 phenotype was alleviated by 2-hydroxypropyl-{beta}-cyclodextrin treatment, a drug demonstrating efficacy both in vitro and in vivo. This NPC1I1061T/I1061T i3Neuronal cell line can facilitate future high-throughput drug and genomic screens, particularly those aimed at identifying proteostasis regulators that improve the expression/stability of the mutant NPC1 protein.
- organism: human
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pharmacological BET Protein Inhibition Reverts Niemann-Pick Type C Disease-Associated Changes in Human iPSC-Derived Cortical Neurons
Federica Benigni, Martina Parente, … Claudia Compagnucci·bioRxiv·Sep 3, 2026
- Correction of Niemann-Pick type C1 disease with the histone deacetylase inhibitor valproic acid
K. Subramanian, D. M. Hutt, … W. E. Balch·bioRxiv·Aug 4, 2019
- Cellular Modeling of CLN6 with IPSC-derived Neurons and Glia
María Gabriela Otero, Jaemin Kim, … Tyler Mark Pierson·bioRxiv·Jan 29, 2024
- Modelling Niemann-Pick disease type C in a human haploid cell line allows for patient variant characterization and clinical interpretation.
Steven Erwood, Reid A. Brewer, … Evgueni A. Ivakine·Genome ResearchPeer-reviewed·Dec 1, 2019
- Severe neurometabolic phenotype in npc1-/- zebrafish with a C-terminal mutation
Ana Quelle‐Regaldie, Nerea Gandoy-Fieiras, … María Jesús Sobrido·Frontiers in Molecular NeurosciencePeer-reviewed·Mar 17, 2023
- HSP90 inhibitors reduce cholesterol storage in Niemann-Pick type C1 mutant fibroblasts
N. H. Pipalia, S. Z. Saad, … F. R. Maxfield·bioRxiv·Apr 22, 2021